Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Outflow Tract Calcification and the Best Valve in This Context

Moderate or severe left ventricle outflow tract calcification increases the risk of annulus rupture, residual aortic regurgitation and the need for a second valve. This recent study analyzed the performance of different contemporary prosthetic valves in patients with this particular anatomy. 

Calcificación del tracto de salida

Since the early days of transcatheter aortic valve replacement (TAVR) outflow tract calcification has been associated to adverse events. In addition, the evidence available was limited to a modest number of observational studies, incomplete followup and the lack of study of the difference devices. 

Moderate or severe calcification was considered with at least 2 nodules, or one extending over 5 mm, or covering over 10% of the outflow tract perimeter.

Of 1635 patients undergoing TAVR, moderate to severe calcification of the outflow tract was documented in nearly 25% of patients (407 patients, 24.9%).

These patients showed a significantly higher risk of annulus rupture (2.3% vs 0.2%; p<0.001), the need for a second valve (2.9% vs 0.8%; p=0.004) and residual aortic failure (11.1% vs. 6.3%; p=0.002).


Read also: ESC 2020 | Ticagrelor Might Increase Bleeding and Mortality in the Elderly.


The balloon expandable valve showed higher risk of annulus rupture in these patients (4.0% vs. 0.4%; p=0.002) vs all the self-expandable valves.

The need for a second valve and residual regurgitation resulted similar across device range. 

Conclusion

Outflow tract calcification increases the risk of annulus rupture, residual aortic regurgitation and the need for a second valve. Annulus rupture resulted far more frequent with the balloon expandable valve, while the rest of complications resulted similar across devices. 

Título original: Impact of Left Ventricular Outflow Tract Calcification on Procedural Outcomes After Transcatheter Aortic Valve Replacement.

Referencia: Taishi Okuno et al. J Am Coll Cardiol Intv 2020;13:1789–99. https://doi.org/10.1016/j.jcin.2020.04.015.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

TAVI in TAVI: Clinical and Hemodynamic Outcomes According to the Type of Prosthesis Used in TAVI-in-TAVI

With the expansion of TAVI to younger and lower surgical risk patients, bioprosthetic valve degeneration and the need for repeat interventions are expected to...

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...